Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.

Johnson & Johnson is acquiring Ollin Biosciences for $2.2 billion upfront, gaining access to OLN324 — a promising bispecific antibody targeting wet AMD and diabetic macular edema. The deal also includes up to $1.125 billion in milestone payments. Blackstone Life Sciences is co-funding the phase 3 program with a $750 million investment in exchange for royalties and milestone payments.
Johnson & Johnson is making a major bet on retinal disease, announcing a definitive agreement to acquire Ollin Biosciences for $2.2 billion upfront — with up to $1.125 billion more tied to regulatory and commercial milestones. The deal is expected to close before year's end.
The star of the acquisition is OLN324, Ollin's phase 3 investigational bispecific antibody designed to target both VEGF and angiopoietin-2 — two key drivers of retinal disease. It's being developed for wet age-related macular degeneration (AMD) and diabetic macular edema (DME), with early data suggesting stronger, more sustained disease control and longer intervals between treatments.
To help fund OLN324's phase 3 program, J&J also struck a separate deal with Blackstone Life Sciences, which will contribute $750 million in exchange for royalties and milestone payments.
By the Numbers:
Why it matters: Wet AMD and DME are leading causes of vision loss worldwide, and current treatments require frequent injections. If OLN324 delivers on its promise of longer-lasting disease control, it could meaningfully reduce treatment burden for millions of patients.